Summary
Inherited deficiency in mephenytoin hydroxylation was observed in a family study. It is important that the propositus was of the extensive metabolizer phenotype for the genetically controlled hydroxylation of debrisoquine. Thus, a genetic polymorphism of drug hydroxylation was suspected for mephenytoin. A population study of mephenytoin hydroxylation, combined with identification of extensive and poor debrisoquine hydroxylation phenotypes, was carried out in 221 unrelated normal volunteers. Twelve of them (5%) exhibited defective aromatic hydroxylation of mephenytoin, and 23 (10%) could be identified as poor metabolizers of debrisoquine. Amongst these 35 subjects with a drug hydroxylation deficiency, 3 (or 0.5%; 1 female, 2 males) displayed both defects simultaneously. A panel study of 10 extensive and 10 poor metabolizers of mephenytoin showed that the ability to perform aromatic hydroxylation of the demethylated mephenytoin metabolite nirvanol (5-phenyl-5-ethylhydantoin) was co-inherited with the mephenytoin hydroxylation polymorphism. Family studies suggested that poor metabolizer phenotypes of nirvanol and mephenytoin were most likely to have the homozygous genotype for an autosomal recessive allele of deficient aromatic drug hydroxylation. Intra-subject comparison of the debrisoquine and mephenytoin hydroxylation phenotypes in these subjects indicated that deficiency in the two drug hydroxylations occurred independently. Consequently, the co-inheritance of extensive and poor hydroxylation of mephenytoin and nirvanol, respectively, represents a new drug hydroxylation polymorphism in man.
Similar content being viewed by others
References
Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187
Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17: 153–155
Inaba T, Otton SV, Kalow W (1980) Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther 27: 547–549
Eichelbaum M, Bertilsson L, Säwe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186
Idle JR (1984) Genes governing the metabolic oxidation of drugs. Occurrence, classification and multiple consequences. In: Rawlins MD, Wilkinson GR (eds) Butterworths international medical reviews, vol 2, Drug metabolism and disposition. Butterworth, London, (in press)
Küpfer A, Preisig R (1983) Inherited defects of hepatic drug metabolism. Semin Liver Disease 3: 341–354
Lu AYH, West SB (1980) Multiplicity of mammalian microsomal Cytochromes P-450. Pharmacol Rev 31: 277–295
Nebert DW (1979) Multiple forms of inducible drug metabolizing enzymes: A reasonable mechanism by which any organism can cope with adversity. Mol Cell Biochem 27: 27–46
Nebert DW (1981) Possible clinical importance of genetic differences in drug metabolism. Br Med J 283: 537–542
Nebert DW, Negishi M (1982) Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution. Biochem Pharmacol 31: 2311–2317
Scott J, Poffenbarger PL (1979) Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28: 41–51
Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL (1982) Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man. Biochem Pharmacol 31: 3151–3154
Penno MB, Vesell ES (1983) Monogenic control of variations in antipyrine metabolite formation. J Clin Invest 71: 1698–1709
Küpfer A, Kick B, Preisig R (1982) A new drug hydroxylation polymorphism in man: The incidence of mephenytoin hydroxylation deficient phenotypes in an European population study. Naunyn-Schmiedeberg's Arch Pharmacol 321: 33
Küpfer A, Desmond PV, Patwardhan R, Schenker S, Branch RA (1984) Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Clin Pharmacol Ther 35: 33–39
Küpfer A, Brilis GM, Watson TJ, Harris TM (1980) A major pathway of mephenytoin metabolism in man: Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab Dispos 8: 1–4
Küpfer A, Roberts RK, Schenker S, Branch RA (1981) Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 218: 193–199
Küpfer A, Desmond PV, Schenker S, Branch RA (1982) Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther 221: 590–597
Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy-metabolite in biological fluids by gas-chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 133: 161–166
Price-Evans DA, Mahgoub A, loan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Küpfer A, Bircher J, Preisig R (1977) Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethyl-hydantoin (Nirvanol) in the dog. J Pharmacol Exp Ther 203: 493–499
Butler TC (1956) The metabolic conversion of 3-methyl-5-ethyl-5-phenylhydantoin (Mesantoin) and of 5-ethyl-5-phenyl-hydantoin (Nirvanol) to 5-ethyl-5-(p-hydroxyphenyl)-hydantoin. J Pharmacol Exp Ther 117: 160–165
Butler TC (1952) Metabolic demethylation of 3-methyl-5-ethyl-5-phenylhydantoin (Mesantoin). J Pharmacol Exp Ther 104: 299–308
Idle JR, Smith RL (1979) Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev 9: 301–317
Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22
Küpfer A, Lawson J, Branch RA (1984) Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man. Epilepsia 25: 1–7
Kutt H, Wolk M, Scherman R, McDowell F (1964) Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 14: 542–548
Gerber N, Lynn R, Oates J (1972) Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Ann Int Med 77: 765–771
Vasko MR, Bell RD, Daly DD, Pippenger CE (1980) Inheritance of phenytoin hypometabolism: A kinetic study of one family. Clin Pharmacol Ther 27: 96–103
Sloan TP, Idle JR, Smith RL (1981) Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 29: 493–497
de Wolff FA, Vermeij P, Ferrari MD, Buruma OJS, Breimer DD (1983) Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Ther Drug Monitor 5: 213–215
Al-Dabbagh SG, Idle JR, Smith RL (1981) Animal modelling of human polymorphic drug oxidation — the metabolism of debrisoquine and phenacetin in inbred rat strains. J Pharm Pharmacol 33: 161–164
Küpfer A, Al-Dabbagh SG, Ritchie JC, Idle JR, Smith RL (1982) Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Biochem Pharmacol 31: 3193–3199
Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373–400
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Küpfer, A., Preisig, R. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26, 753–759 (1984). https://doi.org/10.1007/BF00541938
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541938